The Healthy Alaskan
SEE OTHER BRANDS

Fresh news on health and wellness in Alaska

The Healthy Alaskan: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The Healthy Alaskan.

Press releases published on May 22, 2025

Descriptif du Programme de Rachat d’Actions Pouvant Être Mis en Œuvre dans le Cadre du Contrat de Liquidité Conclu avec Kepler Chevreux

Descriptif du Programme de Rachat d’Actions Pouvant Être Mis en Œuvre dans le Cadre du Contrat de Liquidité Conclu avec Kepler Chevreux

Daix, le 22 mai 2025 En application de l'article 241-2 du Règlement Général de l’Autorité des marchés financiers (AMF), le présent descriptif a pour finalité de présenter les objectifs ainsi que les modalités du programme de rachat d’actions autorisé par l …

Corbus Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

Corbus Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

NORWOOD, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will provide a corporate update and participate …

GRI Bio Presents Positive Pre-Clinical Data Demonstrating GRI-0621 Resolves Inflammation and Fibrosis in Bleomycin-Induced Fibrosis and Reiterates Promising Preliminary Phase 2a Clinical Results

GRI Bio Presents Positive Pre-Clinical Data Demonstrating GRI-0621 Resolves Inflammation and Fibrosis in Bleomycin-Induced Fibrosis and Reiterates Promising Preliminary Phase 2a Clinical Results

Data presented at the 2025 American Thoracic Society (ATS) International Conference Pre-clinical and interim clinical results underscore GRI-0621’s potential to have both anti-inflammatory and anti-fibrotic effects in pulmonary fibrosis Results from 6-week …

Eight recipients honoured with the 2025 Fiera Capital Awards for Diversity, Equity, and Inclusion in Health Care Research

Eight recipients honoured with the 2025 Fiera Capital Awards for Diversity, Equity, and Inclusion in Health Care Research

MONTREAL, May 22, 2025 (GLOBE NEWSWIRE) -- This year, eight exceptional medical and health science students from Black, Indigenous, and other racialized communities have been awarded the 2025 Fiera Capital Awards for Diversity, Equity, and Inclusion in …

Sequel Med Tech to Integrate twiist Automated Insulin Delivery (AID) System with Abbott’s Future Dual Glucose-Ketone Sensor

Sequel Med Tech to Integrate twiist Automated Insulin Delivery (AID) System with Abbott’s Future Dual Glucose-Ketone Sensor

MANCHESTER, N.H., May 22, 2025 (GLOBE NEWSWIRE) -- Sequel Med Tech, LLC, a company developing state-of-the-art insulin delivery technologies today announced a commercial development agreement for future integration of Sequel’s twiist™ Automated Insulin …

Nanox Announces First Quarter 2025 Financial Results and Provides Business Updates

Nanox Announces First Quarter 2025 Financial Results and Provides Business Updates

PETACH TIKVA, Israel, May 22, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, today announced results for the first quarter ended March 31, 2025, and provided a …

Sagimet Biosciences to Host Virtual KOL Event, “Evaluating the Synergistic Potential of a Combination of Denifanstat and Resmetirom for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)” on May 29, 2025

Sagimet Biosciences to Host Virtual KOL Event, “Evaluating the Synergistic Potential of a Combination of Denifanstat and Resmetirom for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)” on May 29, 2025

SAN MATEO, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced it will host a …

Stratus Announces Publication of Stratus PRIME™ HSC Platform in the American Journal of Hematology

Stratus Announces Publication of Stratus PRIME™ HSC Platform in the American Journal of Hematology

First-in-class approach enables the generation of transgene-free hematopoietic stem cells through mechanosensitive PIEZO1 activation Stratus has an exclusive license to the intellectual property for the platform technology – Stratus Prime™ CAMBRIDGE, Mass …

BetterLife Provides Comments on CEO’s Share Position Ownership and Recent BCSC Press Release

BetterLife Provides Comments on CEO’s Share Position Ownership and Recent BCSC Press Release

VANCOUVER, British Columbia, May 22, 2025 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB : BETRF / FRA: NPAU), an emerging biotech company focused on the development of BETR-001, a non-hallucinogenic …

Telix to Host Investor Day in New York City on June 11, 2025

Telix to Host Investor Day in New York City on June 11, 2025

MELBOURNE, Australia and INDIANAPOLIS, May 22, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”, “the Company”) today announces it will host an Investor Day on Wednesday, June 11, 2025, in person, in New York City, …

Petvivo Holdings, Inc. and PiezoBioMembrane Inc. Announce Master Services Agreement to Jointly Develop Innovative Functional Biomaterials

Petvivo Holdings, Inc. and PiezoBioMembrane Inc. Announce Master Services Agreement to Jointly Develop Innovative Functional Biomaterials

MINNEAPOLIS, May 22, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV; OTCPINK: PETVW) and its wholly-owned subsidiary PetVivo Animal Health, Inc. (collectively referred to herein as the "Company" or “PetVivo”) an emerging biomedical device …

Quoin Pharmaceuticals Announces FDA Clearance to Initiate Second Pivotal Whole Body QRX003 Netherton Syndrome Clinical Study

Quoin Pharmaceuticals Announces FDA Clearance to Initiate Second Pivotal Whole Body QRX003 Netherton Syndrome Clinical Study

Study CL-QRX003-002 will test whole-body application of QRX003 in conjunction with off-label systemic therapy in approximately 12-15 subjects. Study CL-QRX003-002 complements first whole-body pivotal study, CL-QRX003-003, being led by Dr. Amy Paller at …

Tilray Medical Brings Canada’s Iconic Cannabis Brand Good Supply to Germany

Tilray Medical Brings Canada’s Iconic Cannabis Brand Good Supply to Germany

NEUMÜNSTER, Germany, May 22, 2025 (GLOBE NEWSWIRE) -- Tilray Medical (“Tilray”), a division of Tilray Brands, Inc. (NASDAQ: TLRY and TSX: TLRY) and a global leader in medicinal cannabis, empowering the therapeutic alliance between patients and healthcare …

Foghorn Therapeutics to Participate in Four Upcoming Investor Conferences

Foghorn Therapeutics to Participate in Four Upcoming Investor Conferences

CAMBRIDGE, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced …

Sernova Biotherapeutics Appoints World-Class Clinical Advisory Board to Support Development of Cell Pouch Bio-hybrid Organ as Functional Cure for Type 1 Diabetes

Sernova Biotherapeutics Appoints World-Class Clinical Advisory Board to Support Development of Cell Pouch Bio-hybrid Organ as Functional Cure for Type 1 Diabetes

LONDON, Ontario and BOSTON, May 22, 2025 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics, (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a leading regenerative medicine company focused on developing its Cell Pouch Bio-hybrid Organ as a functional cure for type 1 …

Replimune Reports Fiscal Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update

Replimune Reports Fiscal Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update

•  BLA priority review of RP1 plus nivolumab in advanced melanoma proceeding on schedule; manufacturing inspections and late cycle review meeting complete •  Full commercial infrastructure for launch in place ahead of July 22nd PDUFA date •  Conference …

Ernst & Young (EY) US Announces Jason Matuszewski, CEO of BioStem Technologies, as an Entrepreneur Of The Year® 2025 Florida Award finalist

Ernst & Young (EY) US Announces Jason Matuszewski, CEO of BioStem Technologies, as an Entrepreneur Of The Year® 2025 Florida Award finalist

POMPANO BEACH, Fla., May 22, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM) (the “Company” or “BioStem”), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced …

Sharps Technology Regains Compliance with Nasdaq Minimum Bid Price Listing Rule

Sharps Technology Regains Compliance with Nasdaq Minimum Bid Price Listing Rule

NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (Nasdaq: “STSS” and “STSSW”) (“Sharps”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class smart-safety syringe products to the healthcare …

Skye Bioscience to Participate in Upcoming Investment Conferences

Skye Bioscience to Participate in Upcoming Investment Conferences

SAN DIEGO, May 22, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today announced that it will …

ANI Pharmaceuticals Announces Initiation of Phase 4 Clinical Trial of Purified Cortrophin® Gel for the Treatment of Acute Gout Flares

ANI Pharmaceuticals Announces Initiation of Phase 4 Clinical Trial of Purified Cortrophin® Gel for the Treatment of Acute Gout Flares

Purified Cortrophin Gel is the only ACTH therapy approved by the FDA for the treatment of acute gout flares Trial to be conducted by Dr. Hyon Choi at Massachusetts General Hospital and will compare the safety and efficacy of two dose levels of Purified …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service